HHLR Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

HHLR Advisors’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,929,708	Closed	-$185M	–	87
2021 Q2	$185M	Sell	2,929,708 -1,628,321	-36%	-$84M	1.91%	16
2021 Q1	$196M	Sell	4,558,029 -470,260	-9%	-$22.3M	1.93%	15
2020 Q4	$288M	Hold	5,028,289	–	–	2.29%	14
2020 Q3	$152M	Hold	5,028,289	–	–	1.15%	17
2020 Q2	$164M	Hold	5,028,289	–	–	1.5%	13
2020 Q1	$135M	Buy	5,028,289 +350,000	+7%	+$12.4M	1.82%	16
2019 Q4	$143M	Hold	4,678,289	–	–	1.78%	16
2019 Q3	$113M	Buy	4,678,289 +2,098,581	+81%	+$57.8M	1.55%	17
2019 Q2	$65.4M	Hold	2,579,708	–	–	1.46%	19
2019 Q1	$50.3M	Buy	2,579,708 +350,000	+16%	+$5.5M	1.4%	17
2018 Q4	$29.4M	Buy	+2,229,708	New	+$34.2M	1.22%	18

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors's APLS Position: Q3 2021 in Review

HHLR Advisors sold out of Apellis Pharmaceuticals (APLS) in Q3 2021, closing a stake of 2,929,708 shares — an estimated $185M sold.

HHLR Advisors first reported a position in APLS in Q4 2018 and held it in 11 quarters. The position peaked at $288M in Q4 2020. 180 funds tracked by Wall St. Rank hold APLS as of Q3 2021.

HHLR Advisors reported no remaining Apellis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
HHLR Advisors sold 2,929,708 Apellis Pharmaceuticals shares in Q3 2021, an estimated $185M.
HHLR Advisors first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 11 quarters.
HHLR Advisors's Apellis Pharmaceuticals position peaked at $288M in Q4 2020.
180 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2021.

Based on HHLR Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.